News | February 23, 2015

Additional PET/CT Scans Valuable in Follow-Up of Lung Cancer Patients

PET/CT scans changed treatment in more than 28 percent of patients

PET/CT, lung cancer, follow-up, tumor tracking, nuclear imaging, trial

February 23, 2015 — New research from Johns Hopkins School of Medicine reveals a high value for scans which could lead to future change of reimbursement policies for follow-up positron emission tomography/computed tomography (PET/CT) studies in lung cancer. The study, featured in the February 2015 issue of The Journal of Nuclear Medicine, establishes the value of fourth and subsequent follow-up PET/CT scans in clinical assessment and management change in patients with the disease.

In the retrospective study, a total of 1,171 patients with biopsy-proven lung cancer who had positron emission tomography with a radioactive tracer (18F-FDG) were identified at a single tertiary center from 2001 to 2013. Among these, 85 patients (7.3 percent) had four or more follow-up PET/CT scans with a total of 285 fourth and subsequent follow-up PET/CT scans. Median follow-up from the fourth scan was 31.4 months. The follow-up PET/CT scan results were correlated with clinical assessment and treatment changes.

Of the 285 fourth and subsequent follow-up PET/CT scans, 149 (52.28 percent) were interpreted as positive and 136 (47.7 percent) were interpreted as negative for recurrence or metastasis. A total of 47 (55.3 percent) patients died during the study period. PET/CT identified recurrence or metastasis in 44.3 percent of scans performed without prior clinical suspicion and ruled out recurrence or metastasis in 24.2 percent of scans performed without prior clinical suspicion. The PET/CT scan resulted in treatment change in 28.1 percent (80/285) of the patients. New treatment was initiated in 20.4 percent (58/285) scan times, treatment was changed in 5.6 percent (16/285) scan times and ongoing treatment was stopped in 2.1 percent (6/285) scan times.

“Although the value of FDG PET/CT has been established in the follow-up of patients with lung cancer, this study specifically looks at the value of the fourth and subsequent follow-up PET/CT studies, which has not been addressed in any prior studies,” stated Rathan Subramaniam, M.D., Ph.D., lead author of the study. “We now need to establish similar evidence for other human solid tumors,” Subramaniam continued.  

The study was performed in the context of the recent Center for Medicaid and Medicare Services declaration that only three FDG PET/CT scans will be covered under section 1862(a)(1)(A) when used to guide subsequent management of anti-tumor treatment strategy after completion of initial anticancer therapy. Coverage of any additional FDG PET/CT scans will be determined by local Medicare administrative contractors. 

For more information: www.snmmi.org

Related Content

Stereotactic Radiosurgery Effective for Pediatric Arteriovenous Malformation Patients
News | Radiation Therapy | April 19, 2019
Ching-Jen Chen, M.D., of the neurosurgery department at the University of Virginia (UVA) Health System, was the winner...
Video Plus Brochure Helps Patients Make Lung Cancer Scan Decision

Image courtesy of the American Thoracic Society

News | Lung Cancer | April 19, 2019
A short video describing the potential benefits and risks of low-dose computed tomography (CT) screening for lung...
Surgically Guided Brachytherapy Improves Outcomes for Intracranial Neoplasms
News | Brachytherapy Systems | April 18, 2019
Peter Nakaji, M.D., FAANS, general practice neurosurgeon at Barrow Neurological Institute, presented new research on...
Oxipit Introduces Multilingual Support for ChestEye AI Imaging Suite
News | Artificial Intelligence | April 16, 2019
The CE-certified ChestEye artificial intelligence (AI) imaging suite by Oxipit is now available in seven European...
Check-Cap Initiates U.S. Pilot Study of C-Scan for Colorectal Cancer Screening
News | Colonoscopy Systems | April 15, 2019
Check-Cap Ltd. has initiated its U.S. pilot study of the C-Scan system for prevention of colorectal cancer through...
Deep Lens Closes Series A Financing for Digital AI Pathology Platform
News | Digital Pathology | April 09, 2019
Digital pathology company Deep Lens Inc. announced the closing of a $14 million Series A financing that will further...
Enlitic Closes Series B Funding for Artificial Intelligence Solutions for Radiologists
News | Artificial Intelligence | April 08, 2019
Radiology artificial intelligence (AI) company Enlitic announced the close of its $15 million Series B financing round...
Uterine Fibroid Embolization Safer and as Effective as Surgical Treatment
News | Interventional Radiology | April 05, 2019
Uterine fibroid embolization (UFE) effectively treats uterine fibroids with fewer post-procedure complications compared...
News | Biopsy Systems | March 29, 2019
Dune Medical Devices has just completed the first in-man cases for Smart Biopsy, its percutaneous soft tissue biopsy...
Artificial Intelligence Can Improve Emergency X-ray Identification of Pacemakers
News | X-Ray | March 29, 2019
A research team from Imperial College London believes a new software could speed up the diagnosis and treatment of...